[{"orgOrder":0,"company":"Medicure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tirofiban Hydrochloride Monohydrate","moa":"||Integrin alpha-IIb\/beta-3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Medicure","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Medicure \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Medicure \/ Undisclosed"},{"orgOrder":0,"company":"Kindai University","sponsor":"Boston Scientific","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Prasugrel","moa":"Purinergic receptor P2Y12","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Kindai University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kindai University \/ Boston Scientific","highestDevelopmentStatusID":"11","companyTruncated":"Kindai University \/ Boston Scientific"},{"orgOrder":0,"company":"Gyeongsang National University Hospital","sponsor":"U&I Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Prasugrel","moa":"Purinergic receptor P2Y12","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Gyeongsang National University Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gyeongsang National University Hospital \/ U&I Corporation","highestDevelopmentStatusID":"11","companyTruncated":"Gyeongsang National University Hospital \/ U&I Corporation"},{"orgOrder":0,"company":"Research Maatschap Cardiologen Rotterdam Zuid","sponsor":"Abbott Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Prasugrel","moa":"Purinergic receptor P2Y12","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Research Maatschap Cardiologen Rotterdam Zuid","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Research Maatschap Cardiologen Rotterdam Zuid \/ Abbott Laboratories","highestDevelopmentStatusID":"11","companyTruncated":"Research Maatschap Cardiologen Rotterdam Zuid \/ Abbott Laboratories"},{"orgOrder":0,"company":"Meditrix","sponsor":"Fujita Health University | Boston Scientific | National University of Ireland, Galway","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Prasugrel","moa":"Purinergic receptor P2Y12","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Meditrix","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Meditrix \/ Fujita Health University | Boston Scientific | National University of Ireland, Galway","highestDevelopmentStatusID":"1","companyTruncated":"Meditrix \/ Fujita Health University | Boston Scientific | National University of Ireland, Galway"}]

Find Clinical Drug Pipeline Developments & Deals for Prasugrel

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Kindai University

                          Country arrow
                          The Battery Show
                          Not Confirmed

                          Kindai University

                          Country arrow
                          The Battery Show
                          Not Confirmed

                          Details : Prasugrel is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of ST Elevation Myocardial Infarction.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          February 02, 2023

                          Lead Product(s) : Prasugrel

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase IV

                          Sponsor : Boston Scientific

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Research Maatschap Cardiologen Rotterdam Zuid

                          Country arrow
                          The Battery Show
                          Not Confirmed

                          Research Maatschap Cardiologen Rotterdam Zuid

                          Country arrow
                          The Battery Show
                          Not Confirmed

                          Details : Prasugrel is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of ST Elevation Myocardial Infarction.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          August 08, 2022

                          Lead Product(s) : Prasugrel

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase IV

                          Sponsor : Abbott Laboratories

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Meditrix

                          Country arrow
                          The Battery Show
                          Not Confirmed

                          Meditrix

                          Country arrow
                          The Battery Show
                          Not Confirmed

                          Lead Product(s) : Prasugrel

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Study Phase : Undisclosed

                          Sponsor : Fujita Health University | Boston Scientific | National University of Ireland, Galway

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Prasugrel is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Acute Coronary Syndrome.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          November 11, 2021

                          Lead Product(s) : Prasugrel

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Undisclosed

                          Sponsor : Fujita Health University | Boston Scientific | National University of Ireland, Galway

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Gyeongsang National University Hospital

                          Country arrow
                          The Battery Show
                          Not Confirmed

                          Gyeongsang National University Hospital

                          Country arrow
                          The Battery Show
                          Not Confirmed

                          Details : Prasugrel is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Coronary Artery Disease.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          February 02, 2021

                          Lead Product(s) : Prasugrel

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase IV

                          Sponsor : U&I Corporation

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          The Battery Show
                          Not Confirmed
                          The Battery Show
                          Not Confirmed

                          Details : The FABOLUS-FASTER trial was designed to assess different regimens of intravenous platelet inhibitors, notably AGGRASTAT® (tirofiban hydrochloride) injection (an IV GP IIb/IIIa inhibitor) and cangrelor (an IV P2Y12 inhibitor) in the early phase of prima...

                          Product Name : Aggrastat

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 15, 2020

                          Lead Product(s) : Tirofiban Hydrochloride Monohydrate,Tirofiban,Prasugrel

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase IV

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank